LANCHBURY JERRY S 4

4 · MYRIAD GENETICS INC · Filed Aug 5, 2021

Insider Transaction Report

Form 4

Period: 2021-08-03

MYRIAD GENETICS INCMYGN

LANCHBURY JERRY S

Executive V.P. - Research

Transactions

Exercise/Conversion
Common Stock
2021-08-03$26.49/sh+16,225$429,800→ 248,775 total
Sale
Common Stock
2021-08-03$33.99/sh−16,225$551,488→ 232,550 total
Sale
Common Stock
2021-08-03$35.07/sh−1,775$62,249→ 232,550 total
Exercise/Conversion
Common Stock
2021-08-03$23.98/sh+27,830$667,363→ 260,380 total
Sale
Common Stock
2021-08-03$34.00/sh−27,830$946,220→ 232,550 total
Exercise/Conversion
Common Stock
2021-08-03$23.98/sh+4,170$99,997→ 236,720 total
Sale
Common Stock
2021-08-03$34.00/sh−4,170$141,780→ 232,550 total
Exercise/Conversion
Common Stock
2021-08-04$27.07/sh+38,225$1,034,751→ 270,775 total
Sale
Common Stock
2021-08-04$35.24/sh−38,225$1,347,171→ 232,550 total
Exercise/Conversion
Common Stock
2021-08-04$27.07/sh+11,775$318,749→ 244,325 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2021-08-04−38,225→ 120,000 total
Exercise: $27.07Exp: 2022-09-12→ Common Stock (38,225 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2021-08-04−11,775→ 108,225 total
Exercise: $27.07Exp: 2022-09-12→ Common Stock (11,775 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2021-08-03−1,775→ 158,225 total
Exercise: $27.07Exp: 2022-09-12→ Common Stock (1,775 underlying)
Exercise/Conversion
Common Stock
2021-08-03$27.07/sh+1,775$48,049→ 234,325 total
Sale
Common Stock
2021-08-04$35.57/sh−11,775$418,856→ 232,550 total
Exercise/Conversion
Incentive Stock Option (right to buy)
2021-08-03−4,170→ 0 total
Exercise: $23.98Exp: 2022-03-07→ Common Stock (4,170 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2021-08-03−27,830→ 0 total
Exercise: $23.98Exp: 2022-03-07→ Common Stock (27,830 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2021-08-03−16,225→ 0 total
Exercise: $26.49Exp: 2021-09-17→ Common Stock (16,225 underlying)

Footnotes (4)

[F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.09 to $35.51, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.57 to $35.58, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]The shares subject to this option are fully vested and exercisable.

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT